InsidersTradesSigma
Total declarations
Companies
▲ Purchases (112 ops.)
▼ Sales (38 ops.)
Insider track record
Board DirectorDisclosed buys
112
Disclosed sells
38
T+90 hit rate
46%
T+90 mean return
+5.9%
Across 37 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by Ra Capital Management, L.p., Board Member. Officer active across 46 companies, notably Werewolf Therapeutics, Inc.. In total, 232 disclosures have been recorded. Breakdown: 112 buys · 38 sells. Total volume traded: €1bn. History available since 26 May 2021. The latest transaction was disclosed on 24 August 2026 (Levée d'options). Regulator: SEC (Form 4). The full history is openly available.
Companies and markets linked to Ra Capital Management, L.p.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations232 total
1,500 shares@ US$3.736Common StockSEC:0001231919-26-001102:0
746,500 shares@ US$42.501.51% mcap100.0% of flowCommon StockSEC:0001231919-26-000938:0
746,500 shares@ US$42.50Common StockSEC:0001231919-26-000938:1
24,944 shares@ US$9.930.051% mcap4.8% of flowCommon StockSEC:0001231919-26-000817:1
Canonical exit: 29 Oct 2026 (T+90)
20,824 shares@ US$9.990.043% mcap4.1% of flowCommon StockSEC:0001231919-26-000817:0
Canonical exit: 27 Oct 2026 (T+90)
18,030,000 sharesCommon StockSEC:0001231919-26-000815:0
41,319 shares@ US$9.990.085% mcap8.9% of flowCommon StockSEC:0001231919-26-000808:0
Canonical exit: 22 Oct 2026 (T+90)
120,582 shares@ US$9.550.24% mcap27.0% of flowCommon StockSEC:0001231919-26-000791:0
Canonical exit: 19 Oct 2026 (T+90)
84,124 shares@ US$9.930.17% mcap19.6% of flowCommon StockSEC:0001231919-26-000791:1
Canonical exit: 20 Oct 2026 (T+90)
6,522 shares@ US$8.940.012% mcap1.4% of flowCommon StockSEC:0001231919-26-000790:0
Canonical exit: 11 Oct 2026 (T+90)
59,880 shares@ US$9.960.12% mcap14.0% of flowCommon StockSEC:0001231919-26-000791:2
Canonical exit: 21 Oct 2026 (T+90)
970,950 sharesCommon StockSEC:0001231919-26-000783:1
336,965 shares@ US$10.006.4% of flowCommon StockSEC:0001231919-26-000783:6
6,504 shares@ US$29.170.0053% mcap2.7% of flowVoting Common StockSEC:0001231919-26-000779:3
Canonical exit: 19 Oct 2026 (T+90)
98,433 shares@ US$27.130.074% mcap38.6% of flowVoting Common StockSEC:0001231919-26-000779:0
Canonical exit: 18 Oct 2026 (T+90)
4,918,411 shares@ US$10.0093.6% of flowCommon StockSEC:0001231919-26-000783:5
21,696 shares@ US$27.960.017% mcap8.8% of flowVoting Common StockSEC:0001231919-26-000779:2
Canonical exit: 19 Oct 2026 (T+90)
37,723 shares@ US$30.000.031% mcap16.4% of flowVoting Common StockSEC:0001231919-26-000779:4
Canonical exit: 19 Oct 2026 (T+90)
367,427 sharesCommon StockSEC:0001231919-26-000783:4
908,103 sharesCommon StockSEC:0001231919-26-000783:3
553,703 sharesCommon StockSEC:0001231919-26-000783:2
6,561,711 sharesCommon StockSEC:0001231919-26-000783:0
32,987 shares@ US$27.720.025% mcap13.2% of flowVoting Common StockSEC:0001231919-26-000779:1
Canonical exit: 18 Oct 2026 (T+90)
47,250 shares@ US$29.770.039% mcap20.4% of flowVoting Common StockSEC:0001231919-26-000779:5
Canonical exit: 20 Oct 2026 (T+90)
2,100,000 shares@ US$0.0020.0003% mcap0.0% of flowCommon StockSEC:0001231919-26-000776:0
25 of 232 declarations
About Ra Capital Management, L.p.
RA CAPITAL MANAGEMENT, L.P. is a Board Member and a declarant with 165 filings in total. In the sampled recent filings, the period runs from 2021-05-06 to 2026-06-29, total buy volume is EUR 739087096 and total sell volume is EUR 70026863. Among the largest filings are Cidara Therapeutics, Inc. at EUR 85526990.77875149, DICE Therapeutics, Inc. at EUR 60793814.59694451, Janux Therapeutics, Inc. at EUR 49586580.54028194, 89bio, Inc. at EUR 47960494.06611299, and Vor Biopharma Inc. at EUR 47350003.24436461 and EUR 42580993.0415421.
